Interest of 2-octyl-cyanoacrylate (Dermabond®) in Closing Surgical Incisions in Children Before Acquisition of Continence

Interest of 2-octyl-cyanoacrylate (Dermabond®) in Closing Surgical Incisions in Children Before Acquisition of Continence. Randomised, Prospective, Non-inferiority Study.

Inguinal incisions are the most frequent incisions used in children before the acquisition of continence (180 incisions per year for the Pediatric Surgery Department in Nice CHU). However, healing of those wounds can be made hard because of soiling induced by urine and/or stool, which is unavoidable in case of wearing nappies.

Nowadays, in order to overcome a possible contamination of the surgical wound, post-surgery wound dressing is protected by the application of a waterproof band aid (like Tegaderm®) during wound-healing (evaluated to a mean of 7 days). When the band aid is soiled, a nurse changes it, causing unpleasantness in low age children (whose epidermal fragility is well known), and sometimes parents worry.

Moreover, those occlusive wound dressings avoid any control of the surgical wound during healing phase.

At the end of the wound-healing time, wound dressings are removed, causing discomfort for children and necessity of a qualified nurse staff at visit times.

Cutaneous use glues, introduced in surgery more than 10 years ago, allow making waterproof and transparent sutures, with a firmness equivalent to a 2/0 string suture (cutaneous suture in children is made with 5/0) and has its own local antiseptic properties. It does not need to be covered by any wound dressing during wound-healing phase. Moreover, cosmetic results for the 2-octyl-cyanoacrylate in the adult and children series (without any precise age distinction) seem to be equivalent to conventional sutures. Finally, its application goes with time saving (in preoperative and during wound-healing phase) and increases comfort for patients.

The aim of this study is to evaluate the efficiency of cutaneous use glue Dermabond® (2-octyl-cyanoacrylate) in surgical inguinal incisions sutures in children before the acquisition of continence, by a non-inferiority randomized multicentric prospective study.

Two patient groups will be studied, the sutures of one control group will be made with a conventional technique (intradermic surjet surgical suture), and one patient group will be sutured with 2-octyl-cyanoacrylate. The principal evaluation criteria is the suture quality (short- and long-term cosmetic aspect) evaluated by the surgeon.

Two secondary criteria will be studied :

  • Parental satisfaction
  • Ease of clinical nursing management Each studied criteria will be evaluated by a numeric score.

Study Overview

Study Type

Interventional

Enrollment (Actual)

89

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alpes Maritimes
      • Nice, Alpes Maritimes, France, 06000
        • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet2
      • Nice, Alpes Maritimes, France, 06000
        • Fondation Lenval -Hôpital Pédiatrique
    • Bouches Du Rhône
      • Marseille, Bouches Du Rhône, France, 13000
        • Assistance Publique Hopitaux de Marseille - Hôpital Timone Enfants
    • Hérault
      • Montpellier, Hérault, France, 34000
        • Centre Hospitalier Universitaire de Montpellier - Hopital Lapeyronie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 2 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children less than 24 months old
  • Continuous nappies wearing for non-acquisition of continence
  • Need of a surgical intervention which entry way is an inguinal incision in the inguinal fold (POTTS incision) for the following indications:

    • inguinal hernia
    • testicular ectopy
    • hydrocele
    • chord cyst
  • Surgical incision smaller than 5 cm
  • Informed consent form signed by both parents or by the legal representative
  • Patient affiliated to French national health and pensions organization

Exclusion Criteria:

  • Chronic or acute dermatological affection that can hamper wound-healing (atopic pathology, infectious pathology…)
  • General affection that can hamper wound-healing (chronic denutrition)
  • Cutaneous infection at the incision site
  • Scar in the concerned region
  • Medical history of wound-healing trouble
  • Digestive pathology causing chronic or acute diarrhea
  • Allergy to one of the used compounds (glue, string, wound dressing)
  • Operative indication set in emergency with immediate surgery
  • Non-acceptance of the protocol, refusal to participate to the study by one of the parents or the legal representative
  • Impossibility of doing the follow up of the child, in accordance with the pre-established rules of the protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cutaneous suture with glue
Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
the cutaneous suture is made with glue only
Other Names:
  • 2-octyl-cyanoacrylate (Dermabond®)
Active Comparator: Conventional suture
Inguinal surgical incision closing with conventional cutaneous suture (surjet)
cutaneous surjet suture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Adequate or suboptimal wound-healing rate defined by a HOLLANDER cosmetic score higher or equal to 5 at the end of the initial wound-healing period.
Time Frame: J7-J10 and J+ 6 month
J7-J10 and J+ 6 month

Secondary Outcome Measures

Outcome Measure
Time Frame
Re-evaluation of the HOLLANDER cosmetic score 6 month after wound-healing.
Time Frame: J0, J7-J10 and J + 6 month
J0, J7-J10 and J + 6 month
Parental satisfaction: 0-100 numeric scale divided in 5 items.
Time Frame: J0, J7-J10 and J + 6 month
J0, J7-J10 and J + 6 month
Nurse satisfaction : 0-100 numeric scale divided in 4 items.
Time Frame: J0, J7-J10 and J + 6 month
J0, J7-J10 and J + 6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean BREAUD, MD, Centre Hospitalier Universitaire de Nice

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2009

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

June 1, 2018

Study Registration Dates

First Submitted

May 28, 2009

First Submitted That Met QC Criteria

May 28, 2009

First Posted (Estimate)

May 29, 2009

Study Record Updates

Last Update Posted (Actual)

July 23, 2018

Last Update Submitted That Met QC Criteria

July 20, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08-PP-10

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inguinal Incisions

Clinical Trials on 2-octyl-cyanoacrylate (Dermabond® glue)

3
Subscribe